{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:52Z","timestamp":1790217412871,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["17411952900"],"award-info":[{"award-number":["17411952900"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470642"],"award-info":[{"award-number":["81470642"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770964"],"award-info":[{"award-number":["81770964"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00417-020-04600-3","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T06:03:55Z","timestamp":1581401035000},"page":"1005-1012","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Subretinal injection of ranibizumab in advanced pediatric vasoproliferative disorders with total retinal detachments"],"prefix":"10.1007","volume":"258","author":[{"given":"Jie","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiquan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"issue":"4587","key":"4600_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1126\/science.6823562","volume":"219","author":"DR Senger","year":"1983","unstructured":"Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219(4587):983\u2013985","journal-title":"Science."},{"issue":"2","key":"4600_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/08820530902800108","volume":"24","author":"KL Lin","year":"2009","unstructured":"Lin KL, Hirose T, Kroll AJ, Lou PL, Ryan EA (2009) Prospects for treatment of pediatric vitreoretinal diseases with vascular endothelial growth factor inhibition. Semin Ophthalmol 24(2):70\u201376","journal-title":"Semin Ophthalmol"},{"issue":"4\u20135","key":"4600_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1537-1891(03)00011-9","volume":"39","author":"DO Bates","year":"2002","unstructured":"Bates DO, Harper SJ (2002) Regulation of vascular permeability by vascular endothelial growth factors. Vasc Pharmacol 39(4\u20135):225\u2013237","journal-title":"Vasc Pharmacol"},{"issue":"6","key":"4600_CR4","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ophtha.2007.08.050","volume":"115","author":"K Sonmez","year":"2008","unstructured":"Sonmez K, Drenser KA, Jr CA, Trese MT (2008) Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 115(6):1065\u20131070","journal-title":"Ophthalmology"},{"issue":"5","key":"4600_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ophtha.2012.01.056","volume":"119","author":"MW Stewart","year":"2012","unstructured":"Stewart MW (2012) Bevacizumab for retinopathy of prematurity. Ophthalmology 119(5):1091","journal-title":"Ophthalmology"},{"issue":"4","key":"4600_CR6","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1111\/aos.12055","volume":"91","author":"Y Xu","year":"2013","unstructured":"Xu Y, Zhang Q, Kang X, Zhu Y, Li J, Chen Y, Zhao P (2013) Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection. Acta Ophthalmol 91(4):e304\u2013e310","journal-title":"Acta Ophthalmol"},{"key":"4600_CR7","unstructured":"Wallace DK (2016) Anti-VEGF treatment for ROP: which drug and what dose? J AAPOS 20(6):476\u2013478"},{"issue":"8","key":"4600_CR8","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","volume":"124","author":"Q Huang","year":"2017","unstructured":"Huang Q, Zhang Q, Fei P, Xu Y, Lyu J, Ji X, Peng J, Li YA, Zhao P (2017) Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology 124(8):1156\u20131164","journal-title":"Ophthalmology"},{"key":"4600_CR9","unstructured":"Wu AL, Wu WC (2018) Anti-VEGF for ROP and pediatric retinal diseases. Asia Pac J Ophthalmol (Phila) 7(3):145\u2013151"},{"issue":"4","key":"4600_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000477744","volume":"238","author":"J Peng","year":"2017","unstructured":"Peng J, Zhang Q, Jin H, Fei P, Zhao P (2017) A modified technique for the transconjunctival and sutureless external drainage of subretinal fluid in bullous exudative retinal detachment using a 24-G i.v. catheter. Ophthalmologica 238(4):6","journal-title":"Ophthalmologica"},{"issue":"4","key":"4600_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000336906","volume":"227","author":"S Ghorbanian","year":"2012","unstructured":"Ghorbanian S, Jaulim A, Chatziralli IP (2012) Diagnosis and treatment of coats\u2019 disease: a review of the literature. Ophthalmologica 227(4):175","journal-title":"Ophthalmologica"},{"issue":"2","key":"4600_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000099247","volume":"39","author":"RB Jia","year":"2007","unstructured":"Jia RB, Zhang P, Zhou YX, Song X, Liu HY, Wang LZ, Luo M, Lu J, Ge SF, Fan XQ (2007) VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma. Ophthalmic Res 39(2):108\u2013115","journal-title":"Ophthalmic Res"},{"issue":"7","key":"4600_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/archopht.126.7.953","volume":"126","author":"SY Lee","year":"2008","unstructured":"Lee SY, Kim DK, Cho JH, Koh JY, Yoon YH (2008) Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma. Arch Ophthalmol 126(7):953\u2013958","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"4600_CR14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/ICB.0000000000000369","volume":"11","author":"M Ho","year":"2017","unstructured":"Ho M, Yip WW, Chan VC, Yong AL (2017) Successful treatment of refractory proliferative retinopathy of incontinentia pigmenti by intravitreal ranibizumab as adjunct therapy in a 4-year-old child. Retin Cases Brief Rep 11(4):352","journal-title":"Retin Cases Brief Rep"},{"issue":"4","key":"4600_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jaapos.2018.01.008","volume":"22","author":"Y Ni","year":"2018","unstructured":"Ni Y, Huang X, Ruan L, Xue K, Yu J, Peng J, Zhao P (2018) Intravitreal injection of ranibizumab in severe retinopathy of incontinentia pigmenti. J AAPOS 22(4):325\u2013327.e3","journal-title":"J AAPOS"},{"issue":"1","key":"4600_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12886-016-0327-9","volume":"16","author":"Y Sun","year":"2016","unstructured":"Sun Y (2016) Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term. BMC Ophthalmol 16(1):150","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"4600_CR17","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","volume":"91","author":"R Hoerster","year":"2013","unstructured":"Hoerster R, Muether P, Dahlke C, Mehler K, Oberthuer A, Kirchhof B, Fauser S (2013) Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol 91(1):e74\u2013e75","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"4600_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00417-015-2996-0","volume":"254","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Jiang Y, Bai Y, Wen J, Chen L (2016) Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol 254(1):1\u20136","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"4600_CR19","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"S Bakri","year":"2007","unstructured":"Bakri S, Snyder M, Reid J, Pulido J, Ezzat M, Singh R (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114(12):2179\u20132182","journal-title":"Ophthalmology"},{"issue":"4","key":"4600_CR20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","volume":"37","author":"WC Wu","year":"2017","unstructured":"Wu WC, Shih CP, Lien R, Wang NK, Chen YP, Chao A, Chen KJ, Ys H, Lai CC (2017) Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina 37(4):694\u2013701","journal-title":"Retina"},{"issue":"1","key":"4600_CR21","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","volume":"11","author":"R Lien","year":"2016","unstructured":"Lien R, Yu MH, Hsu KH, Liao PJ, Chen YP, Lai CC, Wu WC (2016) Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS One 11(1):e0148019","journal-title":"PLoS One"},{"issue":"6","key":"4600_CR22","doi-asserted-by":"publisher","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","volume":"10","author":"L Pertl","year":"2015","unstructured":"Pertl L, Steinwender G, Mayer C, Hausberger S, P\u00f6schl EM, Wackernagel W, Wedrich A, El-Shabrawi Y (2015) A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One 10(6):e0129383","journal-title":"PLoS One"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04600-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-020-04600-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04600-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T06:35:58Z","timestamp":1612938958000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-020-04600-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4600"],"URL":"https:\/\/doi.org\/10.1007\/s00417-020-04600-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]},"assertion":[{"value":"3 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}